Catherine J. Kennedy

Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i> -deficient tubo-ovarian high-grade serous carcinoma

Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions

Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer

Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma

Data from Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Profiling the immune landscape in mucinous ovarian carcinoma

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes

Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp> CD8 ⁺ TIL </scp> infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma

Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma

Therapeutic options for mucinous ovarian carcinoma

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

The molecular origin and taxonomy of mucinous ovarian carcinoma

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

Population based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high grade serous ovarian cancer

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer